DK2830662T3 - Fremgangsmåder til behandlng af hårtabsforstyrrelser - Google Patents

Fremgangsmåder til behandlng af hårtabsforstyrrelser Download PDF

Info

Publication number
DK2830662T3
DK2830662T3 DK13769804.9T DK13769804T DK2830662T3 DK 2830662 T3 DK2830662 T3 DK 2830662T3 DK 13769804 T DK13769804 T DK 13769804T DK 2830662 T3 DK2830662 T3 DK 2830662T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
hair loss
loss disorders
disorders
Prior art date
Application number
DK13769804.9T
Other languages
English (en)
Inventor
Angela M Christiano
Raphael Clynes
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Application granted granted Critical
Publication of DK2830662T3 publication Critical patent/DK2830662T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK13769804.9T 2012-03-29 2013-03-29 Fremgangsmåder til behandlng af hårtabsforstyrrelser DK2830662T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617225P 2012-03-29 2012-03-29
US201261645499P 2012-05-10 2012-05-10
PCT/US2013/034688 WO2013149194A1 (en) 2012-03-29 2013-03-29 Methods for treating hair loss disorders

Publications (1)

Publication Number Publication Date
DK2830662T3 true DK2830662T3 (da) 2019-01-02

Family

ID=49261311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13769804.9T DK2830662T3 (da) 2012-03-29 2013-03-29 Fremgangsmåder til behandlng af hårtabsforstyrrelser

Country Status (12)

Country Link
EP (2) EP3459565A1 (da)
JP (2) JP6212107B2 (da)
KR (1) KR102135601B1 (da)
CN (1) CN104334191A (da)
DK (1) DK2830662T3 (da)
ES (1) ES2694681T3 (da)
HR (1) HRP20181976T1 (da)
HU (1) HUE040127T2 (da)
PL (1) PL2830662T3 (da)
PT (1) PT2830662T (da)
SI (1) SI2830662T1 (da)
WO (1) WO2013149194A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016259023A1 (en) * 2015-05-07 2017-11-30 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth
CN104789689B (zh) * 2015-05-13 2018-10-02 北京泱深生物信息技术有限公司 作为肺腺癌诊治靶标的clec9a基因
KR102774784B1 (ko) 2015-09-25 2025-02-27 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 Jak를 억제하기 위한 화합물 및 방법
JP2017081870A (ja) * 2015-10-30 2017-05-18 学校法人慶應義塾 椎間板変性症に対する治療薬ｊａｋ‐ｓｔａｔ３阻害剤
KR20170101724A (ko) * 2016-02-29 2017-09-06 양지화학 주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민의 용도
CN105695617A (zh) * 2016-04-22 2016-06-22 王冬国 乳头状癌的肿瘤标志物及其应用
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
CA3027428A1 (en) * 2016-06-14 2017-12-21 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
KR101657082B1 (ko) * 2016-08-08 2016-09-13 에스씨엠생명과학 주식회사 CXCL1(chemokine (C-X-C motif) ligand 1) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물
JP2019534304A (ja) * 2016-11-10 2019-11-28 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性疾患の治療のための化合物及びその医薬組成物
CN111032646B (zh) 2017-08-01 2023-01-03 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
WO2019094798A1 (en) 2017-11-10 2019-05-16 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting or inducing hair growth
BR112020024722A2 (pt) 2018-06-04 2021-03-23 Chemistryrx. composições tópicas para estimular crescimento capilar
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
EP3936624A4 (en) * 2019-03-08 2022-11-23 Neogentc Corp. MARKER FOR PREDICTING TUMOR REACTIVITY OF LYMPHOCYTES AND THEIR USE
CN111041095B (zh) * 2019-07-11 2021-11-30 江苏医药职业学院 检测8号染色体开放阅读框73表达水平的试剂的应用和试剂盒
KR102187371B1 (ko) * 2019-08-02 2020-12-04 연세대학교 산학협력단 FoxQ1 유전자가 과발현된 지방유래 줄기세포 및 이의 용도
EP4054527A4 (en) * 2019-11-08 2023-12-06 Cage Bio Inc. TOPICAL ADMINISTRATION OF TOFACITINIB USING IONIC LIQUID
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US20210353600A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Compositions for treating hair loss
FR3111917B1 (fr) * 2020-06-30 2025-04-11 Oreal Signature moléculaire d’un état alopécique commun, associée aux jonctions cellulaires
US20230414511A1 (en) * 2020-11-17 2023-12-28 Arcutis Biotherapeutics, Inc. Compositions and methods for deep dermal drug delivery
AU2022263067A1 (en) * 2021-04-22 2023-11-02 Shenzhen Chipscreen Biosciences Co., Ltd. Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CN116262136A (zh) * 2021-12-13 2023-06-16 复旦大学附属华山医院 以脯氨酰羟化酶为靶点治疗脱发疾病的药物
CN118786125A (zh) * 2022-03-18 2024-10-15 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物的用途及治疗方法
CN114870016B (zh) * 2022-04-21 2023-05-26 上海博悦生物科技有限公司 一种jak抑制剂的微乳泡沫剂及其应用
CN115137832B (zh) * 2022-07-07 2023-11-17 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种jak抑制剂的用途及其抗毛霉感染实验方法
FR3143040A1 (fr) * 2022-12-12 2024-06-14 L'oreal Méthode de pronostic et/ou de diagnostic d’une perte de densité capillaire

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2180526A1 (en) 1994-01-05 1995-07-13 Joseph C. Hogan, Jr. Method of identifying chemical compounds having selected properties for a particular application
US5705625A (en) * 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
CN101028523A (zh) 1995-11-30 2007-09-05 德克萨斯州立大学董事会 诊断和治疗肿瘤的方法及组合物
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
US7419661B2 (en) 1997-04-30 2008-09-02 The Centre Of Excellence For Life Sciences Limited Dermal sheath tissue in wound healing
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP2004504259A (ja) * 1998-06-30 2004-02-12 パーカー　ヒューズ　インスティテュート Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE60017115T2 (de) * 1999-02-10 2005-12-08 Mitsubishi Pharma Corp. Amid-derivate und deren medizinische verwendung
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9925964D0 (en) 1999-11-03 1999-12-29 Jahoda Colin A B Hair transplantation
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6188045B1 (en) 2000-04-03 2001-02-13 Alto-Shaam, Inc. Combination oven with three-stage water atomizer
IE20010387A1 (en) 2000-04-20 2001-11-14 Bernard Mcnamara A swimming pool assembly
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
CA2487679A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004044188A1 (en) 2002-11-14 2004-05-27 Intercytex Limited Cultivation of hair inductive cells
US7884189B2 (en) 2003-01-10 2011-02-08 The Trustees Of Columbia University In The City Of New York Carboxyltransferase domain of acetyl-CoA carboxylase
WO2005105146A1 (en) * 2004-05-03 2005-11-10 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CN101563097A (zh) 2005-11-14 2009-10-21 企业合伙人风险资本公司 用于组织损伤的干细胞生长因子疗法
EP1974044B1 (en) 2005-12-12 2011-01-26 CANJI, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
NZ592968A (en) * 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
BRPI0708347A2 (pt) * 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
US9109204B2 (en) 2006-02-28 2015-08-18 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US7704533B2 (en) * 2006-12-13 2010-04-27 J&J Consumer Companies, Inc. Compositions and methods of inducing hair growth utilizing Continus coggygria
CA2722326A1 (en) * 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2396004A4 (en) * 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
PT2635299T (pt) * 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo

Also Published As

Publication number Publication date
EP3459565A1 (en) 2019-03-27
JP2018027959A (ja) 2018-02-22
PL2830662T3 (pl) 2019-02-28
JP6527565B2 (ja) 2019-06-05
EP2830662B1 (en) 2018-08-29
WO2013149194A1 (en) 2013-10-03
PT2830662T (pt) 2018-11-29
KR20140148459A (ko) 2014-12-31
EP2830662A4 (en) 2015-09-09
HUE040127T2 (hu) 2019-02-28
EP2830662A1 (en) 2015-02-04
KR102135601B1 (ko) 2020-07-20
HRP20181976T1 (hr) 2019-01-25
CN104334191A (zh) 2015-02-04
SI2830662T1 (sl) 2019-01-31
JP6212107B2 (ja) 2017-10-11
JP2015515470A (ja) 2015-05-28
ES2694681T3 (es) 2018-12-26

Similar Documents

Publication Publication Date Title
DK2635299T3 (da) Fremgangsmåder til behandling af hårtabsforstyrrelser
LT2885010T (lt) Tautopatijos gydymo būdai
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK2968208T3 (da) Behandling af kataplexi
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK2846809T3 (da) Behandling af myelosuppression
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK3725778T4 (da) Formuleringer af enzalutamid
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
SI2707029T1 (sl) Metode zdravljenja ali preprečevanja s holesterolom povezanih motenj
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
LT3007726T (lt) Tautopatijos gydymo būdai
DK2897611T3 (da) Fremgangsmåder til behandling af hepatitis c
DK2961426T3 (da) Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g
PL2776055T3 (pl) Sposoby leczenia zaburzeń żołądkowo-jelitowych
BR112013023142A2 (pt) método de tratamento de cabelos
DK3049100T3 (da) Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser